Creative Planning’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Creative Planning’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	-$2K	–	4514
2017 Q2	$2K	Hold	5,000	–	–	﹤0.01%	4386
2017 Q1	$2K	Hold	5,000	–	–	﹤0.01%	4381
2016 Q4	$2K	Hold	5,000	–	–	﹤0.01%	4369
2016 Q3	$3K	Sell	5,000 -5,000	-50%	-$3.36K	﹤0.01%	4177
2016 Q2	$7K	Hold	10,000	–	–	﹤0.01%	3497
2016 Q1	$7K	Hold	10,000	–	–	﹤0.01%	3452
2015 Q4	$7K	Buy	+10,000	New	+$12.6K	﹤0.01%	3547

Other funds holding AXN

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Creative Planning's AXN Position: Q3 2017 in Review

Creative Planning sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q3 2017, closing a stake of 5,000 shares — an estimated $2K sold.

Creative Planning first reported a position in AXN in Q4 2015 and held it in 7 quarters. The position peaked at $7K in Q2 2016. 8 funds tracked by Wall St. Rank hold AXN as of Q3 2017.

Creative Planning reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 5,000 Aoxing Pharmaceutical Company Inc. shares in Q3 2017, an estimated $2K.
Creative Planning first reported a position in Aoxing Pharmaceutical Company Inc. in Q4 2015 and held it in 7 quarters.
Creative Planning's Aoxing Pharmaceutical Company Inc. position peaked at $7K in Q2 2016.
8 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.